Background Carboxylated osteocalcin (Gla-OC) participates in bone remodeling, whereas the
intramolecular disulfide bond, which contributes to stabilizing its three-dimensional structure upon binding of its γ-carboxylated glutamate (Gla) residues to calcium. 3 The undercarboxylated OC (Glu-OC)
does not appear to bind calcium but could be involved in interactions with its recently identified G protein-coupled receptor family C group 6 member A (GPRC6A). 4 It has been demonstrated that it is expressed in many tissues including: liver, skeletal muscle, brain, testis, bone and pancreatic β-cells. [5] [6] [7] Gprc6a −/− mice have more white fat compared with wild-type (WT) animals. They are glucose intolerant, insulin resistant, develop hepatic steatosis and have reduced testosterone levels. 8 All these observations suggested that GPRC6A mediates metabolic function of osteocalcin. Recent studies have shown that carboxylated osteocalcin (Gla-OC) interacts with hydroxyapatite crystals and modulates its growth, whereas the Glu-OC has a hormone-like function in energy metabolism, fertility and brain development. 4, [9] [10] [11] The administration of exogenous Glu-OC into WT mice decreased their fat mass and serum triglyceride (TG) levels. In white adipose tissue, Glu-OC inhibited the expression of lipolysis mediating genes:
triglyceride lipase (Tgl) and perilipin, but activated the expression of adiponectin and its target genes. 12 Osteocalcin affected the expression of Pgc1a, Nrf1, and Mcad -genes implicated in energy consumption and mitochondrial biogenesis in muscles, 13 whereas in the brown adipose tissue expression of genes involved in thermogenesis: Ucp1
and Pgc1a was increased. 12 Osteocalcin was demonstrated to affect glucose uptake in skeletal and vascular muscle cells. 14 It has also been reported that osteocalcin can directly modulate glucose transport in adipocytes, suppress the secretion of proinflammatory cytokines and induce the secretion of anti-inflammatory cytokines as adiponectin. 15 Oury et al 10 have recently demonstrated that disrupting osteocalcin signaling leads to glucose intolerance in both humans and mice, providing evidence that there is some similarity between mouse and human OC in mediated pathways. Several available papers present osteocalcin studies in humans. [16] [17] [18] [19] Patients with type 2 diabetes have been reported to have a lower concentration of serum osteocalcin compared to healthy counterparts. 17 Semenkovich and Teitelbaum 18 suggested existing a cycle in which the metabolic events of diabetes downregulate osteoblast function, which in turn leads to less secretion of osteocalcin and a greater aggravation of insulin resistance. However, results from human studies have been inconsistent and often have implicated total osteocalcin association with insulin sensitivity adipokines and inflammatory markers. 19 This study was undertaken to compare the blood level of Glu-OC and Gla-OC in nonobese, obese (prediabetic) and healthy obese (without biochemical parameters' pathology) volunteers and correlate them with the metabolic markers of insulin resistance and early markers of inflammation.
| MATERIALS AND METHODS

| Subjects and anthropometry
The study protocol and the entire study were approved by the Bioeth- vitamins, β-carotene or n-3 polyunsaturated fatty acids, therapy with:
hormones, anti-inflammatory drugs or other drugs known to affect lipid or glucose metabolism, smoking or excessive use of alcohol, pregnancy or lactation. All patients enrolled into this study were asked to follow an isocaloric diet with a low amount of antioxidative vitamins, polyunsaturated fatty acids and alcohol for 2 weeks before and during the study. The diet instructions were presented to each patient and diet compliance was controlled every 2 weeks by a dietitian.
Body weight was measured to the nearest 0.1 kg with a digital scale, and height was measured to the nearest 0.5 cm using a wallmonitored stadiometer. Waist and hip circumferences were obtained with a tape measure. Body composition was estimated with the bioelectrical impedance method using Segmental Body Composition
Analyser TANITA BC 418 MA (Tanita, Japan). Blood pressure was measured in the supine position after 10 minutes of rest with an automatically inflating cuff. 
| Sample collection and analysis
| Blood analyses
Plasma Gla-OC and Glu-OC were determined by ELISA (Takara, Japan). 
| Statistical analyses
The Shapiro-Wilk test was used to test data for a Gaussian distribution.
Normally distributed data are presented as mean ± SEM otherwise as OLTT were calculated by the trapezoidal method. 23 
| RESULTS
The characteristics of the study population of nonobese and obese participants is presented in Tables 1 and 2 . Obese volunteers (n = 98) differ from nonobese ones (n = 34) in regard to anthropometric measurements: BMI (34.0 vs 28.4 kg/m 2 , P < .001), adipose tissue mass (40.8% vs 35.0%, P < .001), and blood pressure (Table 1) . Patients with higher BMI also showed increased plasma leptin levels and fasting insulin. Area under the OGTT and OLTT insulin concentration-time curve and basal insulin resistance index HOMA-IR were also increased in obese patients (Table 2 ). Subjects in both groups participating in the study did not differ in: plasma fasting and postprandial lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol, TGs, and FFAs) as well as GIP levels.
Serum hsCRP and IL-6 were higher in obese subjects. Plasma levels of ALT, AST, urea, and uric acid were also elevated in this group of patients (Tables 1 and 2 ). In the whole group of obese patients in comparison to nonobese subjects, the level of Gla-OC was significantly lower, whereas there were no significant differences in total osteocalcin as well as Glu-OC content (Table 2) . For further analysis, the whole group of study participants (n = 132) was divided into 2 groups (Table 3 ) or 4 groups (Table 4 ) in accordance to the higher Gla-OC (>11.2 ng/mL) and the lower Gla-OC (<11.2 ng/mL) level based on the median value. We observed that the group with lower Gla-OC level (n = 66) demonstrated a lower amount of Glu-OC, and Gla/Glu ratio, which was accompanied by higher blood concentrations of inflammatory cytokines: hsCRP and visfatin. In this group of patients, lower levels of total and LDL cholesterol, sPECAM-1, urea, creatinine and higher eGFR were observed in comparison with subjects presenting Gla-OC higher than 11.2 ng/mL (Table 3) . A weak negative correlation of Gla-OC with: hsCRP (r = −0.18, P = .042), visfatin concentration (r = −0.19, P = .033), BMI (r = −0.17, P = .047) and eGFR (r = −0.31, P = .000) was found (Table 5) . No correlation of Gla-OC with insulin resistance parameters (fasting Insulin, HOMA-IR or glucose levels) was found (Table 5) . On the contrary, Glu-OC inversely correlated with fasting insulin level and HOMA IR index ( Table 5 ). Comparison of nonobese and obese subjects regarding Gla-OC levels (Table 4) showed that obese patients with Gla-OC >11.2 ng/mL presented higher Glu-OC, total
and LDL cholesterol as well as sPECAM-1 level than obese ones with Gla-OC <11.2 ng/mL. Such results were not observed in the group of nonobese subjects (Table 4) . Obese subjects with a Gla-OC level less than 11.2 ng/mL demonstrated higher plasma hsCRP level than nonobese ones. Therefore, for further analysis, the group of obese subjects was divided in accordance to metabolic disturbances. We selected healthy obese subjects (without any metabolic disturbances) (n = 29) and obese patients presenting symptoms of prediabetes with or without atherogenic dyslipidemia (n = 32). The group with prediabetes included subjects whose fasting plasma glucose was ≥5.6 and <7.0 mmol/L or the level of glucose at the 2 hours of OGTT was between 7.8 and 11 mmol/L. Lipid disturbances were considered when serum fasting TG level was ≥1.7 mmol/L or the HDL cholesterol concentration in men was <1.03 mmol/L and in women <1.29 mmol/L (Table 6 ).
Healthy obese volunteers presented higher Glu-OC level than those from the obese group with prediabetic disturbances (Table 6 ).
Insulin resistance symptoms (glucose, insulin, and HOMA-IR) as well as GIP levels were significantly higher in volunteers with prediabetes (Table 6 ). The segregation of all obese subjects (n = 98) into 2 subgroups based on Glu-OC level (Glu-OC <2.97 ng/mL and Glu-OC >2.97 ng/mL) revealed that subjects with lower levels of undercarboxylated osteocalcin (n = 49) demonstrated increased fasting insulin levels and insulin resistance index HOMA IR (Table 7) , pointing to decreased insulin sensitivity. On the contrary, no elevation of the investigated biochemical markers of inflammation was found in this group (Table 7 ).
Thus, the lower level of Glu-OC in obese subjects characterized the subjects with insulin resistance expressed by the increased fasting plasma insulin and HOMA-IR values, whereas the Gla-OC level correlated with the markers of inflammatory status indicated in our study by the elevation of blood hsCRP and visfatin level.
Gla-OC/Glu-OC ratio had a tendency to distinguish obese healthy individuals from prediabetic subjects ( Table 6 ). The Gla-OC/Glu-OC ratio correlated: positively with fasting insulin and HOMA-IR index in obese subjects, negatively with inflammatory markers (hsCRP and sVCAM) in obese prediabetic participants, and inversely with sEselectin in nonobese patients (Table 8) . Our findings confirmed that osteocalcin is an osteoblast-specific secreted protein, which participates not only in bone remodeling but also in metabolism regulation. Bone remodeling is highly dependent on the energetic status of the organism. For example, anorexia nervosa and insulin-dependent diabetes mellitus are associated with osteoporosis, while a higher BMI is associated with increased bone mass. 25 The hormones implicated in the regulation of food intake and energy metabolism (ie, leptin, adiponectin and incretins) also regulate bone mass.
26-28
High-fat diet (HFD) induces insulin resistance in osteoblasts and leads to a decrease in circulating levels of the active form of osteocalcin (thereby decreasing insulin sensitivity in skeletal muscle and WAT). 29 Insulin resistance developed in osteoblasts is suggested to be the result of increased levels of free saturated fatty acids, which promote SMURF1-mediated insulin receptor (INSR) ubiquitination and its subsequent degradation in osteoblasts. 7 These experiments support the notion that insulin resistance in bone contributes to the deleterious consequences of a long-term HFD on whole-body glucose homeostasis, in part because it decreases the activity of osteocalcin. 7 Osteocalcin is γ-carboxylated on the glutamic acids (GLU) 13, 17, and 20 of protein in mouse, and on GLU 17, 21, and 24 in humans. Low as well as high carbohydrate meals resulted in decreased concentrations of osteocalcin over time. Henriksen et al 31 showed that oral ingestion of long chain triacylglycerides had no effect on osteocalcin concentration.
In our studies, a decreased level of Gla-OC in obese patients was observed. The Gla-OC concentration in serum inversely correlated with markers associated with low-grade inflammation in obesity:
hsCRP and visfatin. Our results are in agreement with in vitro studies, which revealed anti-inflammatory properties of osteocalcin. In experiments conducted on primary-cultured adipocytes, Hill et al 15 showed
that both forms of osteocalcin suppressed the secretion of tumor necrosis factor alpha into the media. However, only carboxylated osteocalcin suppressed IL-6 release. Both carboxylated and uncarboxylated osteocalcin increased the secretion of adiponectin TABLE 5 Spearman rank correlation between Gla-OC, Glu-OC, and metabolic variables in the entire group of subjects participating in the study (n = 132) r P Gla-OC and BMI −0.17 .047
Gla-OC and hsCRP −0.18 .042
Gla-OC and visfatin −0.19 .033
Gla-OC and total cholesterol 0.22 .011
Gla-OC and LDL cholesterol 0.3 .000
Gla-OC and urea 0.25 .004
Gla-OC and creatinine 0.28 .002
Gla-OC and MDRD −0.31 .000
Glu-OC and fasting insulin −0.18 .049
Glu-OC and HOMA-IR −0.17 .058
Statistically significant correlations: P < .05. BMI indicates body mass index; Gla-OC, carboxylated osteocalcin; Glu-OC, undercarboxylated osteocalcin; HOMA-IR, homeostatic model assessment; hsCRP, high-sensitivity Creactive protein; MDRD, an estimated Glomerular Filtration Rate (eGFR) calculated from serum creatinine using the Modification of Diet in Renal Disease; LDL, low-density lipoprotein.
TABLE 6
Comparison between the subgroup of obese patients without biochemical markers of metabolic syndrome ("healthy obese") and obese patients with biochemical markers of metabolic syndrome (prediabetic patients)
Obese healthy (n = 29)
Obese with metabolic disturbances in prediabetes (n = 32) P* between Gla-OC and Glu-OC) and hsCRP, [32] [33] [34] we are the first to show this association for the carboxylated osteocalcin form.
However, the mechanism linking hsCRP and bone metabolism is not well understood. The anti-inflammatory effect of Gla-OC could that the severity of glucose intolerance and insulin resistance is in part a consequence of osteoblast-dependent insulin resistance. In obese individuals, total OC has been described to be associated with skeletal muscle but not hepatic insulin sensitivity, whereas undercarboxylated OC is uniquely associated with β-cell function only in individuals with impaired fasting glucose. phosphorylates inhibitory serine residues of the insulin receptor and insulin receptor substrates and thereby blocking insulin action. 43 IKKβ phosphorylation leads to the activation of nuclear factor-κB-mediated pathways, including the inflammatory one. These results underscore the involvement of bone (among other tissues) in the disruption of glucose homeostasis resulting from lipotoxicity and involvement of insulin and osteocalcin cross talk in glucose intolerance. 4, [6] [7] [8] 10, 13, 44 Along with this, is the recent demonstration that disrupting osteocalcin signaling in humans leads to glucose intolerance. Using mouse models, Oury et al found that osteocalcin and LH act in 2 parallel pathways and that osteocalcin-stimulated testosterone synthesis is positively regulated by bone resorption and insulin signaling in osteoblasts. 10 In humans, they analyzed a cohort of patients with primary testicular failure and identified 2 individuals harboring the same heterozygous missense variant in one of the transmembrane domains of GPRC6A, which prevented the receptor from localizing to the cell membrane. It was a point mutation in exon 4 of GPRC6A, resulting in F464Y amino acid substitution. This missense mutation affects a highly conserved residue, occurring in one of the transmembrane regions of the molecule and preventing its localization to the cell membrane, therefore resulting in a loss of function of GPRC6A. Patients harboring this substitutionmutation demonstrated higher fasting insulin and glucose levels as well as pathological OGTT parameters. Thus, insulin resistance in bone might contribute to whole-body insulin resistance in patients with type 2 diabetes. 10 Interestingly, it has recently been determined that the known detrimental effect of glucocorticoids on glucose metabolism could be in part explained by its negative action on osteocalcin production. 45 Recent publications in mouse models suggest that the protective effect of osteocalcin on obesity and insulin resistance might be, at least in part, due to its capacity to increase adiponectin release and energy expenditure in brown adipose tissue and skeletal muscle. 12, 13, 15 As mentioned previously, we did not observe any correlation between osteocalcin forms and adiponectin. Similar to our results, Wang et al 46 reported that total osteocalcin inversely correlated with HbA1c, and Glu-OC inversely correlated with fasting blood glucose. However, no significant correlation was found between osteocalcin and HOMA-IR.
The implementation of the Gla/Glu or Glu-OC/total OC ratio was suggested for finding an association between Glu-OC and metabolic syndrome parameters in children. 47 In our study, the presence of biochemical markers of prediabetes resulted in an increase in the Gla-OC/Glu-OC ratio value in comparison with healthy obese subjects.
Of note, the Gla/Glu ratio value correlated positively with insulin resistance markers in obese patients and negatively with markers of inflammation in nonobese controls and in obese patients with metabolic disturbances.
However, the study has potential limitations, namely, an unequal number of both sexes and the small number of subjects in the study.
Another limitation of the study is the small number of control group participants in comparison to obese subjects. So far, osteocalcin findings have shown that Glu-OC and Gla-OC are bystander markers rather than mechanistic ones. Data from human studies concerning these 2 markers are rather inconsistent, and their mechanism of action is not fully understood. Therefore, we postulate that the results of our study could be a base for further studies explaining the mechanism of osteocalcin action in larger groups of subjects. Our results argue for the suggestion that the decreased blood concentration of Glu-OC may be an early symptom of insulin resistance development in obesity, whereas the decreased level of Gla-OC seems to be connected with early symptoms of obesity associated inflammation in humans.
